Institutional members access full text with Ovid®

Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance

Boffito, Martaa; Winston, Alana; Jackson, Akila; Fletcher, Carla; Pozniak, Antona; Nelson, Marka; Moyle, Graemea; Tolowinska, Izabelaa; Hoetelmans, Richardb; Miralles, Diegob; Gazzard, Briana

doi: 10.1097/QAD.0b013e3282170ab1
Epidemiology and Social

Background: Cumulative antiretroviral exposure can result in multiclass HIV drug resistance. Experimental antiretroviral agents offer limited therapeutic benefit as resistance quickly develops after their introduction as a sole new agent.

Objective: To assess the pharmacokinetic profile, safety and virological response of two novel investigational antiretroviral agents when used in combination in HIV-1-infected subjects with multidrug-resistant virus.

Methods: HIV-1-infected subjects, with current virological failure on a stable antiretroviral regimen with no viable treatment options were assigned to a regimen comprising two new investigational agents, etravirine, a novel nonnucleoside reverse transcriptase inhibitor, and darunavir, a novel protease inhibitor, plus nucleoside reverse transcriptase inhibitors (and enfuvirtide in selected patients) for 24 weeks. Virological, immunological and safety parameters were collected. Detailed pharmacokinetic assessments of darunavir and etravirine were determined on days 7 and 28.

Results: Follow up of 24 weeks was achieved by 10/12 patients. Median reduction in HIV RNA was 2.7 log10 copies/ml (range, 2.3–3.9) and increase in CD4 lymphocytes was 113 cells/μl (range, 41–268). HIV RNA was < 40 copies/ml in nine. No serious adverse events were recorded. Plasma exposure to darunavir was similar to historic control data and exposure to etravirine similar to historic data when etravirine was administered with a boosted protease inhibitor.

Conclusion: This first study to assess the use of etravirine and darunavir in HIV-1-infected subjects with no treatment options showed highly effective virological and immunological responses over 24 weeks of therapy with no new safety concerns or unexpected pharmacokinetic interactions.

From the aSt Stephen's Centre, Chelsea and Westminster Hospital, London, UK

bTibotec BVBA, Mechelen, Belgium.

Received 31 October, 2006

Revised 8 March, 2007

Accepted 16 March, 2007

Correspondence to Dr M. Boffito, St Stephen's Centre, Chelsea and Westminster Hospital, 369 Fulham Rd, London, SW10 9NH, UK. E-mail: marta.boffito@chelwest.nhs.uk

© 2007 Lippincott Williams & Wilkins, Inc.